SARS-CoV-2 variants of concern Alpha and Delta show increased viral load in saliva

Background Higher viral loads in SARS-CoV-2 infections may be linked to more rapid spread of emerging variants of concern (VOC). Rapid detection and isolation of cases with highest viral loads, even in pre- or asymptomatic individuals, is essential for the mitigation of community outbreaks. Methods and Findings In this study, we analyze Ct values from 1297 SARS-CoV-2 positive patient saliva samples collected at the Clemson University testing lab in upstate South Carolina. Samples were identified as positive using RT-qPCR, and clade information was determined via whole genome sequencing at nearby commercial labs. We also obtained patient-reported information on symptoms and exposures at the time of testing. The lowest Ct values were observed among those infected with Delta (median: 22.61, IQR: 16.72–28.51), followed by Alpha (23.93, 18.36–28.49), Gamma (24.74, 18.84–30.64), and the more historic clade 20G (25.21, 20.50–29.916). There was a statistically significant difference in Ct value between Delta and all other clades (all p.adj<0.01), as well as between Alpha and 20G (p.adj<0.05). Additionally, pre- or asymptomatic patients (n=1093) showed the same statistical differences between Delta and all other clades (all p.adj<0.01); however, symptomatic patients (n=167) did not show any significant differences between clades. Our weekly testing strategy ensures that cases are caught earlier in the infection cycle, often before symptoms are present, reducing this sample size in our population. Conclusions COVID-19 variants Alpha and Delta have substantially higher viral loads in saliva compared to more historic clades. This trend is especially observed in individuals who are pre- or asymptomatic, which provides evidence supporting higher transmissibility and more rapid spread of emerging variants. Understanding the viral load of variants spreading within a community can inform public policy and clinical decision making.


Abstract: 26
Background 27 Higher viral loads in SARS-CoV-2 infections may be linked to more rapid spread of emerging 28 Variants of Concern. Rapid detection and isolation of cases with highest viral loads, even in pre-29 or asymptomatic individuals, is essential for the mitigation of community outbreaks. 30

Methods and Findings 31
In this study, we analyze Ct values from 1297 SARS-CoV-2 positive patient saliva samples 32 collected at the Clemson University testing lab in Upstate South Carolina. Samples were 33 identified as positive using RT-qPCR, and clade information was determined via whole genome 34 sequencing at nearby commercial labs. We also obtained patient-reported information on 35 symptoms and exposures at the time of testing. The lowest Ct values were observed among 36 those infected with Delta (median: 22.61, IQR: 16.72-28.51), followed by Alpha (23.93, 28.49), Gamma (24.74,, and the more historic clade 20G (25.21, 20.50-29.916). 38 There was a statistically significant difference in Ct value between Delta and all other clades (all 39 p.adj<0.01), as well as between Alpha and 20G (p.adj<0.05). Additionally, pre-or asymptomatic 40 patients (n=1093) showed the same statistical differences between Delta and all other clades 41 (all p.adj<0.01); however, symptomatic patients (n=167) did not show any significant differences 42 between clades. Our weekly testing strategy ensures that cases are caught earlier in the 43 infection cycle, often before symptoms are present, reducing this sample size in our population. 44 Conclusions 45 COVID-19 variants Alpha and Delta have substantially higher viral loads in saliva compared to 46 more historic clades. This trend is especially observed in individuals who are pre-or 47 asymptomatic, which provides evidence to the high transmissibility and rapid spread of 48 emerging variants. Understanding the viral load of variants spreading within a community can 49 inform public policy and clinical decision making. 50 51 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted February 15, 2022. ; proximity. Saliva has been shown to be an accurate diagnostic tool, yielding comparable Ct 78 values to NP swabs while decreasing both discomfort to patients and risk of transmission to 79 healthcare workers during collection [10]. 80

Methods: 81
Ethical review for this study was obtained by the Institutional Review Board of Clemson 82 University. This is a retrospective study on archived deidentified samples and data. The 83 samples and data sets were striped of patient identifiers prior to any SARS-CoV2 sequencing 84 and data analysis. To evaluate the relative viral load of the variants of concern (VOC) found in 85 upstate South Carolina (Alpha, Gamma, and Delta), we compared the Ct values from saliva 86 samples from the SARS-CoV-2 testing lab at Clemson University, which also provides free 87 testing for the surrounding community [11]. University surveillance testing is mandatory for 88 students and employees on a weekly or bi-weekly schedule regardless of vaccination status 89 [12]. The study population includes all university students and employees, as well as members 90 of the surrounding community that tested positive between January and November 2021. 91 Samples were labeled as "symptomatic" if the patient self-reported symptoms at the time of 92 collection, or "exposed" if they reported recent viral exposure. All other samples were 93 considered "surveillance". Only one positive test was included for each patient; any subsequent 94 tests were excluded from our analysis. 95 SARS-CoV-2 positive saliva samples were identified using the TigerSaliva RT-qPCR 96 testing method, which targets the N gene [11]. Positive controls made from synthetic RNA at 97 200 viral copies/μL resulted in a Ct value of approximately 24. It was also determined that a Ct 98 of 33 was equivalent to 1 viral copy/μL, and as such any samples with a Ct lower than 33 were 99 considered positive. Samples were run in duplicate, and the average Ct value from both 100 replicates was used for this analysis. 101 Heat treated saliva samples were commercially sequenced (Premier Medical Sciences,102 Greenville, SC; Labcorp, Durham, NC) using the ARTIC protocol. Briefly, RNA was extracted 103 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We first determined the clade composition in our community from the sequenced 117 positive samples between January and December 2021 (Fig 1). From January to July, we 118 sequenced all positive samples stored from the lab. Due to the increase in positive samples 119 during the Delta surge, we sequenced a statistical sampling of positives (approximately 15%) to 120 ensure accurate coverage of our community demographics. 121 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To compare Ct values, and thereby infectious potential, statistical analyses were 127 performed in an R environment using Kruskal-Wallis test followed by Dunn's test of multiple 128 comparisons (Fig 2). SARS-CoV-2 positive samples showed a significant difference between 129 CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted February 15, 2022. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted February 15, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 When analyzing only symptomatic samples, we found no statistically significant 148 difference in Ct values amongst the clades (Fig 2C). The benefit of Clemson University's 149 surveillance strategy is that infections are caught early, often before symptoms are present, 150 which decreases the number of symptomatic samples in our population. While there are 151 significant differences in viral loads between the VOC clades and 20G in pre-symptomatic and 152 asymptomatic patients at the time of initial diagnosis, this trend is not necessarily maintained as 153 the disease progresses. This may explain the discordant results in the literature; studies which 154 primarily focused on tests from COVID-19 hospitalized patients did not observe differences in 155 viral loads among the clades [6], whereas studies that included tests from earlier stage 156 diagnoses observed significant differences in viral loads, particularly for Delta [4,5]. 157 Additionally, patients that report symptoms are much more likely to test positive 158 compared to non-symptomatic patients (Fig 3). From January to November 2021, the average 159 positivity rate for symptomatic samples was 12.71% and for surveillance samples was 0.98%. 160 During the surge in cases due to the Alpha variant in March 2021, samples from patients at the 161 community site who reported exposure were much more likely to be positive for SARS-CoV-2 162 when compared to non-exposed (8.8% vs 1.7%). However, after the emergence of Delta, the 163 test positivity rate was 10% in both groups. This is likely due to the overwhelming presence of 164 Delta within our community and the extremely high viral load, likely ensuring that everyone had 165 some level of exposure. 166 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted February 15, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022  testing, or labeled "exposed" if they report exposure to a positive patient. Surveillance samples 170 represent the rest of the samples collected. The lower case load during week 11 is due to the 171 university's spring break, and weeks 18-29 account for summer break. 172 173 Due to a non-normal data distribution, we performed Kruskal-Wallis test for stochastic 174 dominance. However, it has been suggested that ANOVA is robust to slight non-normality [16]. 175 Reanalyzing the data with Welch's ANOVA, we observed similar results (SFig 1) and 176 determined there was approximately an 8-fold difference in viral load between Delta and 20G,177 which is consistent with other studies using NP swabs from initial diagnostic samples [4,5]. Our 178 results highlight the significant difference in Ct values between Delta samples and other VOCs. 179 9 a . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Conclusion: 180
Overall, our study showcases the increased viral load of the Delta variant and provides 181 evidence for its rapid global spread. A major benefit to saliva-based testing is the ease of 182 testing; people are more inclined to test frequently. Specifically, our data show that the Delta 183 VOC has a higher viral load in saliva even in healthy, young individuals who are pre-or 184 asymptomatic. These individuals are not often captured by other studies as they are not likely to 185 seek out testing; however, they are known to contribute to the rapid spread of . 186 High infectivity of new variants necessitates accurate surveillance. It is expected that future 187 dominant strains, like the newly emerging Omicron, will have viral loads comparable to or 188 greater than Delta to achieve a competitive advantage. 189 190 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 15, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022